Novel Therapeutic for the Treatment of COPD

**OCR Number:** OCR 4715

**Description:**

- Chronic Obstructive Pulmonary Disease (COPD), including emphysema and chronic bronchitis, leads to a major irreversible loss of lung function.
- COPD is the third leading cause of death in the US.
- A tremendous unmet medical need exists for effective treatment options for COPD.
- Inhibition of the IL-18 receptor (IL-18R) has been identified as a therapeutic intervention of COPD induced by cigarette smoke (CS).
- IL-18R signaling plays a critical role in the pathogenesis of CS-induced inflammation and emphysema.

*In vivo* studies using antibodies against IL-18R in animal models of COPD have demonstrated significant efficacy in reducing inflammation and cell death.

**Published/Issued Patents:** [U.S. Pub. App. No. 20100247538](https://www.uspto.gov/patents-application-status/)  

**Licensing Contact:** John Puziss  
john.puziss@yale.edu